newsfilter
← Latest News
Business Wire·

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

MYMD-1® development to continue through fully funded mid-stage clinical trials Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with